

Jan stergren

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/323536/jan-ostergren-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

69
papers

16,412
citations

30
h-index

70
g-index

70
ext. papers

18,446
ext. citations

8.8
avg, IF

5.43
L-index

#	Paper	IF	Citations
69	Changes in 24-h ambulatory blood pressure following restoration of sinus rhythm in patients with atrial fibrillation. <i>Journal of Hypertension</i> , 2021 , 39, 243-249	1.9	0
68	Ambulatory blood pressure monitoring and blood pressure control in patients with coronary artery disease-A randomized controlled trial. <i>International Journal of Cardiology: Hypertension</i> , 2021 , 8, 100074	1.6	1
67	Associations Between Crowding and Ten-Day Mortality Among Patients Allocated Lower Triage Acuity Levels Without Need of Acute Hospital Care on Departure From the Emergency Department. <i>Annals of Emergency Medicine</i> , 2019 , 74, 345-356	2.1	24
66	Why Medical Students Choose to Use or Not to Use a Web-Based Electrocardiogram Learning Resource: Mixed Methods Study. <i>JMIR Medical Education</i> , 2019 , 5, e12791	5	2
65	Systolic blood pressure increases in patients with atrial fibrillation regaining sinus rhythm after electrical cardioversion. <i>Journal of Clinical Hypertension</i> , 2019 , 21, 363-368	2.3	5
64	Significant changes in emergency department length of stay and case mix over eight years at a large Swedish University Hospital. <i>International Emergency Nursing</i> , 2019 , 43, 50-55	2.4	7
63	High beat-to-beat blood pressure variability in atrial fibrillation compared to sinus rhythm. <i>Blood Pressure</i> , 2018 , 27, 249-255	1.7	19
62	Physicians' and nurses' perceptions of patient safety risks in the emergency department. <i>International Emergency Nursing</i> , 2017 , 33, 14-19	2.4	28
61	Reasons for interrupting colleagues during emergency department work - A qualitative study. <i>International Emergency Nursing</i> , 2016 , 29, 21-26	2.4	7
60	Factors influencing clinicians' perceptions of interruptions as disturbing or non-disturbing: A qualitative study. <i>International Emergency Nursing</i> , 2016 , 27, 11-6	2.4	14
59	Improvement of blood pressure control and physicians' management over time in patients with coronary artery disease. <i>Blood Pressure</i> , 2016 , 25, 286-91	1.7	1
58	Contributing factors to errors in Swedish emergency departments. <i>International Emergency Nursing</i> , 2015 , 23, 156-61	2.4	24
57	Amlodipine+benazepril is superior to hydrochlorothiazide+benazepril irrespective of baseline pulse pressure: subanalysis of the ACCOMPLISH trial. <i>Journal of Clinical Hypertension</i> , 2015 , 17, 141-6	2.3	3
56	Amino-terminal pro-B-type natriuretic peptide and high-sensitivity C-reactive protein but not cystatin C predict cardiovascular events in male patients with peripheral artery disease independently of ambulatory pulse pressure. <i>American Journal of Hypertension</i> , 2014 , 27, 363-71	2.3	11
55	Corrigendum to Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved [Eur J Heart Fail 2014;16:3340]. <i>European Journal of Heart Failure</i> , 2014 , 16, 592-592	12.3	2
54	Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved. <i>European Journal of Heart Failure</i> , 2014 , 16, 33-40	12.3	141
53	Predictors of systolic BP. <i>Blood Pressure</i> , 2012 , 21, 82-7	1.7	3

52	Ambulatory pulse pressure predicts cardiovascular events in patients with peripheral arterial disease. <i>Blood Pressure</i> , 2012 , 21, 227-32	1.7	7
51	Does individual learning styles influence the choice to use a web-based ECG learning programme in a blended learning setting?. <i>BMC Medical Education</i> , 2012 , 12, 5	3.3	19
50	Dyslipidemia is a strong predictor of myocardial infarction in subjects with chronic kidney disease. <i>Annals of Medicine</i> , 2012 , 44, 262-70	1.5	19
49	Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. <i>American Heart Journal</i> , 2011 , 162, 900-6	4.9	93
48	Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. <i>European Journal of Heart Failure</i> , 2010 , 12, 557-65	12.3	51
47	Change in blood pressure during hospitalisation for acute heart failure predicts mortality. <i>Scandinavian Cardiovascular Journal</i> , 2010 , 44, 325-30	2	2
46	Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. <i>Diabetes Care</i> , 2009 , 32, 915-20	14.6	49
45	Where are we with the management of hypertension? From science to clinical practice. <i>Journal of Clinical Hypertension</i> , 2009 , 11, 66-73	2.3	12
44	Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. <i>Journal of the American College of Cardiology</i> , 2008 , 52, 2000-7	15.1	39
43	Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: the ACCOMPLISH study. <i>Blood Pressure</i> , 2008 , 17, 7-17	1.7	41
42	The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. <i>European Heart Journal</i> , 2008 , 29, 499-508	9.5	77
41	Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. <i>European Heart Journal</i> , 2008 , 29, 2641-50	9.5	135
40	Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. <i>European Heart Journal</i> , 2008 , 29, 1377-85	9.5	419
39	The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. <i>Journal of Hypertension</i> , 2008 , 26, 2103-11	1.9	83
38	Evaluation of a web-based ECG-interpretation programme for undergraduate medical students. <i>BMC Medical Education</i> , 2008 , 8, 25	3.3	49
37	Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence:results from the CHARM Echocardiographic Substudy-CHARMES. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 687-94	15.1	216
36	Myocardial ischaemia in patients with peripheral arterial disease. <i>Clinical Physiology and Functional Imaging</i> , 2007 , 27, 30-5	2.4	1
35	Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. <i>European Journal of Heart Failure</i> , 2007 , 9, 510-7	12.3	38

34	Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>Circulation</i> , 2007 , 115, 3111-20	16.7	188
33	Renin-angiotensin-system blockade in the prevention of diabetes. <i>Diabetes Research and Clinical Practice</i> , 2007 , 76 Suppl 1, S13-21	7.4	24
32	Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). <i>European Heart Journal</i> , 2007 , 28, 88-136	9.5	889
31	Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. <i>European Heart Journal</i> , 2006 , 27, 2982-8	9.5	121
30	From hypertension to heart failure -- are there better primary prevention strategies?. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2006 , 7, 64-73	3	29
29	Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. <i>Circulation</i> , 2006 , 113, 671-8	16.7	694
28	Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. <i>Circulation</i> , 2006 , 113, 986-94	16.7	194
27	Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. <i>European Heart Journal</i> , 2006 , 27, 1447-58	9.5	29
26	Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. <i>American Heart Journal</i> , 2006 , 151, 985-91	4.9	90
25	Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a randomised controlled trial. <i>Lancet, The</i> , 2005 , 366, 895-903	40	2253
24	Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). <i>Lancet, The</i> , 2005 , 366, 907-13	40	269
23	Plasma NT-proBNP concentration is related to ambulatory pulse pressure in peripheral arterial disease. <i>Blood Pressure</i> , 2005 , 14, 99-106	1.7	20
22	Impact of Cigarette Smoking in High-Risk Patients Participating in a Clinical Trial. A Substudy from the Heart Outcomes Prevention Evaluation (HOPE) Trial. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2005 , 12, 75-81		21
21	Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. <i>JAMA - Journal of the American Medical Association</i> , 2005 , 294, 1794-8	27.4	54
20	Candesartan for the treatment of hypertension and heart failure. <i>Expert Opinion on Pharmacotherapy</i> , 2004 , 5, 1589-97	4	11
19	Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. <i>Lancet, The</i> , 2003 , 361, 1149-58	40	2873
18	Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. <i>Lancet, The</i> , 2003 , 362, 759-66	40	1506
17	Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. <i>Lancet, The</i> , 2003 , 362, 767-71	40	1502

16	Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. <i>Lancet, The</i> , 2003 , 362, 772-6	40	1362
15	Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. <i>Lancet, The</i> , 2003 , 362, 777-81	40	2087
14	Angiotensin receptor blockers in heart failure. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2003 , 4, 171-5	3	4
13	Skin microvascular dilatation response to acetylcholine and sodium nitroprusside in peripheral arterial disease. <i>Clinical Physiology and Functional Imaging</i> , 2002 , 22, 370-4	2.4	12
12	Factors predicting success rate and recurrence of atrial fibrillation after first electrical cardioversion in patients with persistent atrial fibrillation. <i>Clinical Cardiology</i> , 2001 , 24, 238-44	3.3	99
11	Regression of left ventricular mass with captopril and metoprolol, and the effects on glucose and lipid metabolism. <i>Blood Pressure</i> , 2001 , 10, 101-10	1.7	20
10	Effect of intravenous magnesium on heart rate and heart rate variability in patients with chronic atrial fibrillation. <i>American Journal of Cardiology</i> , 1999 , 84, 104-8, A9	3	19
9	Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. <i>Journal of Cardiac Failure</i> , 1999 , 5, 276-82	3.3	224
8	Urokinase reduced the need for open surgical procedures in acute ischemia of the leg. <i>Evidence-based Cardiovascular Medicine</i> , 1998 , 2, 82		
7	Effect of amlodipine versus felodipine extended release on 24-hour ambulatory blood pressure in hypertension. <i>American Journal of Hypertension</i> , 1998 , 11, 690-6	2.3	11
6	Adrenaline responsiveness in mild hypertension: no evidence for altered beta-adrenoceptor sensitivity. <i>Journal of Cardiovascular Pharmacology</i> , 1998 , 32, 753-9	3.1	3
5	Comparison of CNS-related subjective symptoms in hypertensive patients treated with either a new controlled release (CR/ZOK) formulation of metoprolol or atenolol. <i>Journal of Clinical Pharmacology</i> , 1990 , 30, S82-90	2.9	16
4	Acrodermatitis chronica atrophicans Herxheimer can often mimic a peripheral vascular disorder. <i>Acta Medica Scandinavica</i> , 1986 , 220, 485-8		6
3	Skin capillary blood cell velocity in patients with arterial obliterative disease and polycythaemia: a disturbed reactive hyperaemia response. <i>Clinical Physiology</i> , 1985 , 5, 35-43		22
2	Theophylline antagonizes cardiovascular responses to dipyridamole in man without affecting increases in plasma adenosine. <i>Acta Physiologica Scandinavica</i> , 1984 , 121, 165-71		102
1	Videophotometric capillaroscopy for evaluating drug effects on skin microcirculation--a double-blind study with nifedipine. <i>Clinical Physiology</i> , 1984 , 4, 169-76		16